Early Detection of Cardiac Toxicity in Childhood Cancer Survivors

Stopped early

Conditions studied: Heart Failure, Cardiotoxicity

In brief

To evaluate cardiac MRI and/or serum biomarkers for detecting cardiac cardiac toxicity in children who received anthracycline based chemotherapy (ABC).

Key facts

Study ID

NCT03038997

Run by

Niti Dham

People needed

42

Starts

2014-11-01

Expected to finish

2018-03-11

Last updated by the study team

2018-12-04

Who can join

Age: 8 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects that have received anthracycline based chemotherapy
• Age: 8 years old - 25 years old
• Subjects that do not require sedation for cardiac MRI.
• Subjects must have completed treatment in the last 10 years

You may not qualify if…

• Patients with significant congenital heart defects
• Patients with renal injury or renal failure, defined as an estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2 body surface area), as previously calculated)
• Patients that require sedation for a cardiac MRI
• Subjects that are pregnant or lactating
• Patients with contraindications to a cardiac MRI:
• Cardiac pacemaker or implantable defibrillator
• Cerebral aneurysm clip
• Neural stimulator
• Metallic ocular foreign body
• Any implanted device (i.e. insulin pump, drug infusion device)
• Claustrophobia
• Metal shrapnel or bullet
• Investigator assessment of inability to comply with protocol
• Unable/unwilling to lie still throughout the research procedure
• Persons with cognitive impairment

Where it is running

• Children's National Health System — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.